Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

Darrin M. Beaupre, MD
Published: Thursday, Mar 30, 2017



Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

In a phase Ib/II trial combination of ibrutinib with lenalidomide (Revlimid) and rituximab (Rituxan) was tested in patients with the ABC subtype of DLBCL. Safety was determined first, and then in the phase II portion, the combination was tested at the maximum-tolerated dose. Ibrutinib with lenalidomide and rituximab was well tolerated up to a 25 mg dose of lenalidomide.

In the non-GCB subtype, there was a high overall response rate, and several patients did not have disease progression until after 1 year, says Beaupre.
 


Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

In a phase Ib/II trial combination of ibrutinib with lenalidomide (Revlimid) and rituximab (Rituxan) was tested in patients with the ABC subtype of DLBCL. Safety was determined first, and then in the phase II portion, the combination was tested at the maximum-tolerated dose. Ibrutinib with lenalidomide and rituximab was well tolerated up to a 25 mg dose of lenalidomide.

In the non-GCB subtype, there was a high overall response rate, and several patients did not have disease progression until after 1 year, says Beaupre.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x